ORYZON provides a corporate update in the context of COVID-19

MADRID, SPAIN and CAMBRIDGE MA.

Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a public clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announces today that, since the emergence of the COVID-19 pandemic, the company has been implementing and executing contingency plans necessary to ensure the health and safety of its employees, partners and clinical trial participants. These plans have been formulated to enable business continuity, and allow the company to fulfill its responsibility to continue developing experimental drugs for serious illnesses with unmet medical needs.

Click here to see the full Press Release